Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin

European Journal of Pediatrics

Volumn 163, Issue 1, 2004, Pages 25-29

  Miura, Masaru ^a,d   Katada, Yasuki ^b   Ishihara, Jun ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Saitama Municipal Hospital   (Japan)

^c YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^d Keio Northwestern Clinic   (United States)

Author keywords

Additional intravenous immune globulin therapy; Kawasaki disease; Measles vaccine

Indexed keywords

IMMUNOGLOBULIN; MEASLES ANTIBODY; MEASLES VACCINE;

ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG INDICATION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; OUTCOMES RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SERODIAGNOSIS;

ANTIBODIES; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALE; MEASLES VACCINE; MUCOCUTANEOUS LYMPH NODE SYNDROME; TIME FACTORS;

EID: 0742304098     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-003-1335-3     Document Type: Article

References (16)

1. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP for The US/Canadian Kawasaki Syndrome Study Group (1998) Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatric Infect Dis J 17: 1144-1148
2. Cohn ML, Robinson ED, Faerber M, Thomas D, Geyer S, Peters S, Martin M, Martin A, Sobel D, Jones R, Larkin L, Richert JR (1994) Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. Pediatr Infect Dis J 13; 34-38
3. Committee on Infectious Diseases, American Academy of Pediatrics (1994) Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. Pediatrics 93: 682-685
4. Han RK, Silverman ED, Newman A, McCrindle BW (2000) Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 154: 694-699
5. Kuijpers TW, Wiegman A, van Lier RAW, Roos MTL, Wertheim-van Dillen PME, Pinedo S, Ottenkamp J and the Holland/Flevoland Kawasaki Disease Study Group (1999) Kawasaki disease: a maturational defect in immune responsiveness. J Infect Dis 180: 1869-1877
6. Mason WH, Takahashi M, Schneider T (1993) Duration of passively acquired measles antibody and response to live virus vaccination following gamma globulin therapy for Kawasaki disease. In: Takahashi M, Taubert K (eds) Proceedings of the fourth international symposium on Kawasaki disease. American Heart Association, pp 515-519
7. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, Mason WH, Meissner HC, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen FS (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Eng J Med 324: 1633-1639
8. Ohsaki M, Tsutsumi H, Takeuchi R, Kuniya Y, Chiba S (1999) Reduced passive measles immunity in infants of mothers who have not been exposed to measles outbreaks. Scand J Infect Dis 31: 17-19
9. Seo SK, Malak SF, Lim S, Eagan J, Sepkowitz KA (2002) Prevalence of measles antibody among young adult healthcare workers in a cancer hospital: 1980s versus 1998-1999. Infect Control Hosp Epidemiol 23: 276-278
10. Siber GR, Werner BG, Halsey NA, Reid R, Almeido-Hill J, Garrett SC, Thompson C, Santosham M (1993) Interference of immune globulin with measles and rubella immunization. J Pediatr 122: 204-211
11. Sonobe T (1994) Intravenous gamma-globulin therapy and vaccination (in Japanese). Shoni-naika 26: 1929-1933
12. Sonobe T, Sakiyama Y, Furukawa S, Harada K, Yamaguchi H, Seki I, Asai H, Suzuki Y, Nagashima M, Matsuoka H, Suzuki J, Nishibayashi Y, Kotani N, Seto S, Furusho K, Kawasaki T (1991) Study of immunity in patients with Kawasaki disease after gamma-globulin therapy: measles antibody and vaccination (in Japanese). Report of research on handicapped patients by The Ministry of Health and Welfare in the Heisei 3 fiscal year: studies on total care of chronic diseases in children, pp 39-42
13. Stetler HC, Orenstein WA, Bernier RH, Herrmann KL, Sirotkin B, Hopfensperger D, Schuh R, Albrecht P, Lievens AW, Brunell PA (1986) Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics 77: 471-476
14. Wallace CA, French JW, Kahn SJ, Sherry DD (2000) Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 105: E78
15. Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, Rowley AH (2002) Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 105: 766-769
16. Zaitsu M, Hamasaki Y, Tashiro K, Matsuo M, Ichimaru T, Fujita I, Tasaki H, Miyazaki S (2000) Ulinastatin, an elastase inhibitor, inhibits the increases mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis 181: 1101-1109